Kevin Johnson previously sat on the Board of Directors for ClearPath Diagnostics, a realized Shore portfolio company. He has over 26 years of experience in the lab diagnostics industry. From 1996 until 2003, Kevin served as Chairman, Chief Executive Officer and President of DIANON Systems, Inc., a publicly-traded cancer diagnostic services company. During that time, DIANON grew annual revenues from approximately $56 million to approximately $200 million, and the company's market capitalization grew from $45 million to approximately $600 million when it was sold to Laboratory Corporation of America (NYSE: LH) in January of 2003. Prior to joining DIANON, Mr. Johnson was employed by Quest Diagnostics and Quest's predecessor, the Life Sciences Division of Corning, Inc., for 18 years, and held numerous management and executive level positions.
Mr. Johnson received a Bachelor of science degree in Business Administration from St. John's University.